TerminatedPhase 4

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Stopped: Blood sugar status of the enrolled subjects wasn't evaluable

United States2 participantsStarted 2013-11-27

Plain-language summary

To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Must be followed by the Inova Fairfax Hospital transplantation program for post-transplant care
✓. Diabetes mellitus inadequately responsive to lifestyle modification and non-insulin hypoglycemic medication
✓. Need for subcutaneous insulin therapy (after discontinuation of IV insulin therapy, if it was required)
✓. Ability to read consent form and give consent in English.

Exclusion criteria

✕. Use of insulin or non-insulin hypoglycemic medication before transplantation
✕. Cystic fibrosis patients
✕. Age \< 18 years of age
✕. Pregnancy
✕. Non-English speaking subjects

What they're measuring

Change in Hemoglobin A1C (Glycosylated Hemoglobin)

Timeframe: at 6 months post enrollment

Trial details

NCT IDNCT01963728

SponsorInova Health Care Services

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-04-09

Results submitted2017-08-15

View on ClinicalTrials.gov More Diabetes Mellitus trials